tbuckley/cabot-search huggingface dataset:
Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
Authors: David E. Kloecker, Melanie J. Davies, Kamlesh Khunti, Francesco Zaccardi
Journal: Annals of Internal Medicine (2020)

The restricted mean survival time (RMST) has been advocated as an alternative or a supplement to the hazard ratio for reporting the effect of an intervention in a randomized clinical trial. The RMST difference allows quantification of the postponement of an outcome during a specified (restricted) interval and corresponds to the difference between the areas under the 2 survival curves for the intervention and control groups. This article presents examples of the use of the RMST in a research and a clinical context. First, the authors demonstrate how the RMST difference can answer research questions about the efficacy of different treatments. Estimates are presented for the effects of pharmacologic or strategy-driven glucose-lowering interventions for adults with type 2 diabetes from 36 trials and 9 follow-up studies reporting cardiovascular outcomes and mortality. The authors show how these measures may be used to mitigate uncertainty about the efficacy of intensive glucose control. Second, the authors demonstrate how the RMST difference may be used in the setting of a clinical consultation to guide the decision to start or discontinue a treatment. They then discuss the advantages of the RMST over the absolute risk difference, the number needed to treat, and the median survival time difference. They argue that the RMST difference is both easy to interpret and flexible in its application to different settings. Finally, they highlight the major limitations of the RMST, including difficulties in comparing studies of heterogeneous designs and in inferring the long-term effects of treatments using trials of short duration, and summarize the available statistical software for calculating the RMST.
TCT-156 Are we closing the Gender Gap in 2017? Vascular Complications following Common Femoral Arterial Access: Then and Now
Authors: Hari Bogabathina, Sampath Singireddy, Nachiket Apte, Khagendra Dahal, Aditya Hendrani, Liam Morris, Runhua Shi, Abdulrahman Abdulbaki, Henock Zabher, Kalgi Modi
Journal: Journal of the American College of Cardiology (2017)
The future of sleep health: a data-driven revolution in sleep science and medicine
Authors: Ignacio Perez-Pozuelo, Bing Zhai, Joao Palotti, Raghvendra Mall, Michaël Aupetit, Juan M. Garcia-Gomez, Shahrad Taheri, Yu Guan, Luis Fernandez-Luque
Journal: npj Digital Medicine (2020)

In recent years, there has been a significant expansion in the development and use of multi-modal sensors and technologies to monitor physical activity, sleep and circadian rhythms. These developments make accurate sleep monitoring at scale a possibility for the first time. Vast amounts of multi-sensor data are being generated with potential applications ranging from large-scale epidemiological research linking sleep patterns to disease, to wellness applications, including the sleep coaching of individuals with chronic conditions. However, in order to realise the full potential of these technologies for individuals, medicine and research, several significant challenges must be overcome. There are important outstanding questions regarding performance evaluation, as well as data storage, curation, processing, integration, modelling and interpretation. Here, we leverage expertise across neuroscience, clinical medicine, bioengineering, electrical engineering, epidemiology, computer science, mHealth and human-computer interaction to discuss the digitisation of sleep from a inter-disciplinary perspective. We introduce the state-of-the-art in sleep-monitoring technologies, and discuss the opportunities and challenges from data acquisition to the eventual application of insights in clinical and consumer settings. Further, we explore the strengths and limitations of current and emerging sensing methods with a particular focus on novel data-driven technologies, such as Artificial Intelligence.
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure
Authors: Susan Stienen, Khibar Salah, Arno H. Moons, Adrianus L. Bakx, Petra van Pol, R. A. Mikael Kortz, João Pedro Ferreira, Irene Marques, Jutta M. Schroeder-Tanka, Jan T. Keijer, Antoni Bayés-Genis, Jan G.P. Tijssen, Yigal M. Pinto, Wouter E. Kok
Journal: Circulation (2017)

Background: The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), with only limited success. The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients with acute decompensated HF using a relative NT-proBNP target has not been investigated. This study aimed to assess whether NT-proBNP-guided therapy of patients with acute decompensated HF using a relative NT-proBNP target would lead to improved outcomes compared with conventional therapy. Methods: We conducted a prospective randomized controlled trial to study the impact of in-hospital guidance for acute decompensated HF treatment by a predefined NT-proBNP target (&gt;30% reduction from admission to discharge) versus conventional treatment. Patients with acute decompensated HF with NT-proBNP levels &gt;1700 ng/L were eligible. After achieving clinical stability, 405 patients were randomized to either NT-proBNP-guided or conventional treatment (1:1). The primary end point was dual: a composite of all-cause mortality and HF readmissions in 180 days and the number of days alive out of the hospital in 180 days. Secondary end points were all-cause mortality within 180 days, HF readmissions within 180 days, and a composite of all-cause mortality and HF readmissions within 90 days. Results: Significantly more patients in the NT-proBNP-guided therapy group were discharged with an NT-proBNP reduction of &gt;30% (80% versus 64%, P =0.001). Nonetheless, NT-proBNP-guided therapy did not significantly improve the combined event rate for all-cause mortality and HF readmissions (hazard ratio, 0.96; 95% confidence interval, 0.72–1.37; P =0.99) or the median number of days alive outside of the hospital (178 versus 179 days for NT-proBNP versus conventional patients, P =0.39). Guided therapy also did not significantly improve any of the secondary end points. Conclusions: The PRIMA II trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) demonstrates that the guidance of HF therapy to reach an NT-proBNP reduction of &gt;30% after clinical stabilization did not improve 6-month outcomes. Clinical Trial Registration: URL: http://www.trialregister.nl . Unique identifier: NTR3279.
Medicaid Expansion and Childhood Cancer Care
Authors: John D. Lantos
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak
Authors: Giulio G. Stefanini, Elena Azzolini, Gianluigi Condorelli
Journal: Circulation (2020)

ombardy, in northern Italy, is one of the regions most affected by coronavirus disease 2019 (COVID-19) secondary to severe acute respiratory syndrome coronavirus 2 infection. 1,2Since the first case diagnosed on February 20, 2020, in Codogno Hospital (Lodi, Lombardy, Italy), the infection has rapidly spread throughout Lombardy, reaching 28,761 confirmed cases, with 3776 deaths as of March 23, 2020.As cardiologists working in this situation, we are facing many critical issues about organizational aspects of management and treatment of cardiovascular disease because of reorganization of the Regional Health Service in response to this epidemic. 3 REORGANIZATION OF CLINICAL ACTIVITIES FOR CARDIOLOGISTSBecause of the reorganization of the Regional Health Service, available resources for cardiology (eg, ward beds, intensive care unit beds, outpatient clinics) have been drastically
Covid-19 mass testing facilities could end the epidemic rapidly
Authors: Julian Peto
Journal: BMJ (2020)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Covid-19 mass testing facilities could end the epidemic rapidly Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
TCT-161 Impact of Pre-existent Prosthesis-Patient Mismatch on Survival Following Aortic Valve-in-Valve Procedures
Authors: Matheus Simonato dos Santos, Philippe Pibarot, Marco Barbanti, Axel Linke, Ran Kornowski, Tanja Rudolph, Gabriel Aldea, Marco Mennuni, Alessandro Iadanza, Hafid Amrane, Diego Gaia, Won Kim, Massimo Napodano, Hardy Baumbach, Ariel Finkelstein, Junjiro Kobayashi, Stephen Brecker, Creighton Don, Alfredo Cerillo, Axel Unbehaun, David Attias, Mohammed Nejjari, Noah Jones, Didier Tchetche, Raphael Philippart, Konstantinos Spargias, Jose Maria Hernandez, Azeem Latib, Danny Dvir
Journal: Journal of the American College of Cardiology (2017)
12 MONTHS CLINICAL OUTCOMES OF TRANSRADIAL CORONARY INTERVENTION : COMPARISON OF THE RIGHT AND LEFT RADIAL ARTERY APPROACH
Authors: Ji Young Park, Seung-Woon Rha, Choi Jaewoong, Sung Kee Ryu, Byoung Geol Choi, Dong Joo Oh, Moo Kim, Myung Ho Jeong, Sang-Yong Yoo, Junghan Yoon
Journal: Journal of the American College of Cardiology (2014)
TCT-379 Percutaneous Transcatheter Aortic Valve Closure Successfully Treats Left Ventricular Assist Device-Associated Aortic Insufficiency and Improves Cardiac Hemodynamics
Authors: Kishan Parikh, Amit Mehrotra, Mark Russo, Roberto Lang, Allen Anderson, Valluvan Jeevanandam, Benjamin Freed, Jonathan Paul, Janet Karol, Sandeep Nathan, Atman Shah
Journal: Journal of the American College of Cardiology (2012)
TCTAP A-079 Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Diabetic Patients with Chronic Total Occlusion
Authors: Li Hu, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
A rare codon-based translational program of cell proliferation
Authors: Joao C. Guimaraes, Nitish Mittal, Alexandra Gnann, Dominik Jedlinski, Andrea Riba, Katarzyna Buczak, Alexander Schmidt, Mihaela Zavolan
Journal: Genome biology (2020)

The speed of translation elongation is primarily determined by the abundance of tRNAs. Thus, the codon usage influences the rate with which individual mRNAs are translated. As the nature of tRNA pools and modifications can vary across biological conditions, codon elongation rates may also vary, leading to fluctuations in the protein production from individual mRNAs. Although it has been observed that functionally related mRNAs exhibit similar codon usage, presumably to provide an effective way to coordinate expression of multiple proteins, experimental evidence for codon-mediated translation efficiency modulation of functionally related mRNAs in specific conditions is scarce and the associated mechanisms are still debated.
VASOACTIVE AGENT USE PRIOR TO ACUTE MECHANICAL CIRCULATORY SUPPORT FOR CARDIOGENIC SHOCK IS ASSOCIATED WITH END ORGAN DYSFUNCTION AND MORTALITY
Authors: Kevin Morine, Michele Esposito, Shiva Annamalai, Robert Pedicini, Lena Jorde, Kyle Gobeil, Jaime Hernandez Montfort, Navin Kapur
Journal: Journal of the American College of Cardiology (2018)
Recurrent architecture for adaptive regulation of learning in the insect brain
Authors: Claire Eschbach, Akira Fushiki, Michael Winding, Casey M. Schneider-Mizell, Mei Shao, Rebecca Arruda, Katharina Eichler, Javier Valdes-Aleman, Tomoko Ohyama, Andreas S. Thum, Bertram Gerber, Richard D. Fetter, James W. Truman, Ashok Litwin-Kumar, Albert Cardona, Marta Zlatic
Journal: Nature Neuroscience (2020)
OUTCOMES OF MEDICARE BENEFICIARIES WITH HEART FAILURE AND ATRIAL FIBRILLATION
Authors: Prateeti Khazanie, Li Liang, Laura Qualls, Lesley Curtis, Gregg Fonarow, Bradley Hammill, Stephen Hammill, Paul Heidenreich, Frederick Masoudi, Adrian Hernandez, Jonathan Piccini
Journal: Journal of the American College of Cardiology (2013)
TCT-753 Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prosthesis
Authors: Taishi Okuno, Faisal Khan, Masahiko Asami, Fabien Praz, Mirjam Winkel, Jonas Lanz, Adrian Huber, Christoph Gräni, Lorenz Raber, Stefan Stortecky, Marco Valgimigli, Stephan Windecker, Thomas Pilgrim
Journal: Journal of the American College of Cardiology (2019)
TCT-431 RANDOMIZED COMPARISON OF ABSORB BIORESORBABLE VASCULAR SCAFFOLD AND MIRAGE MICROFIBER SIROLIMUS ELUTING SCAFFOLD USING MULTI-MODALITY IMAGING
Authors: Teguh Santoso, Huong Bang Liew, Erhan Tenekecioglu, Ricardo Costa, Daniel Chamie, Solomon Su, Alexandre Abizaid, Christos Bourantas, Ryo Torii, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2016)
Effective delivery of mycophenolic acid by oxygen nanobubbles for modulating immunosuppression
Authors: Muhammad Saad Khan, Jae-Sung Kim, Jangsun Hwang, Yonghyun Choi, Kyungwoo Lee, Yejin Kwon, Jaehee Jang, Semi Yoon, Chul-Su Yang, Jonghoon Choi
Journal: Theranostics (2020)

Immunosuppressive drugs are crucial for preventing acute graft rejection or autoimmune diseases.They are generally small molecules that require suitable drug carriers for ensuring stability, bioavailability, and longer half-life.Mycophenolic acid (MPA) is an extensively studied immunosuppressive drug.However, it requires suitable carriers for overcoming clinical limitations.Currently, lipid-shelled micro-and nanobubbles are being thoroughly investigated for diagnostic and therapeutic applications, as they possess essential properties, such as injectability, smaller size, gaseous core, high surface area, higher drug payload, and enhanced cellular penetration.Phospholipids are biocompatible and biodegradable molecules, and can be functionalized according to specific requirements.Methods: In this study, we synthesized oxygen nanobubbles (ONBs) and loaded the hydrophobic MPA within the ONBs to generate ONB/MPA.Peripheral blood mononuclear cells (PBMCs) were treated with ONB/MPA to determine the suppression of immune response by measuring cytokine release.In vivo murine experiments were performed to evaluate the effectiveness of ONB/MPA in the presence of inflammatory stimulants.Results: Our results suggest that ONBs successfully delivered MPA and reduced the release of cytokines, thereby controlling inflammation and significantly increasing the survival rate of animals.Conclusion: This method can be potentially used for implantation and for treating autoimmune diseases, wherein immunosuppression is desired.
IMPACT OF THIN CAPPED-FIBROATHEROMA ON THROMBUS BURDEN IN ACUTE CORONARY SYNDROME : AN OPTICAL COHERENCE TOMOGRAPHY ANALYSIS
Authors: Sharath K. Kumar, Sang-Wook Kim, Doo II Kim, Jee-Eun Kwon, Seong-Hyeop Hyeon, Kim Ki Seok, Lee Wang Soo, Seung Yong Shin
Journal: Journal of the American College of Cardiology (2014)
Abstract 12573: A Hybrid Artificial Intelligence-Intrinsic Frequency Method for Instantaneous Detection of Acute Myocardial Infarction
Authors: Rashid Alavi, Wangde Dai, Robert A Kloner, Niema M Pahlevan
Journal: Circulation (2019)

Introduction: We recently introduced a novel systems-based approach, the Intrinsic Frequency (IF) method, for noninvasive evaluation of the cardiovascular dynamics using non-calibrated arterial pre...
Abstract AP31: ATR INHIBITION TARGETS TREATMENT RESISTANT OVARIAN CANCER
Authors: Hyoung Kim, Erin George, Haineng Xu, Sergey Medvedev, Veena Jagannathan, Mark Morgan, Gordon Mills, Eric Brown, Fiona Simpkins
Journal: Clinical Cancer Research (2019)

Abstract Introduction: Although new treatments for ovarian cancer have been developed with the introduction of Poly (ADP-ribose) polymerase inhibitors (PARPi) to standard of care platinum chemotherapy, the majority of tumors acquire drug resistance. Strategies to circumvent PARPi and platinum resistance are needed and our study addresses this gap. We hypothesize that PARPi resistant tumors are dependent on ATR/CHK1 for DNA repair, and by targeting ATR in combination with PARPi would be more effective in eradicating tumor growth. Experimental Procedures: Drug resistant cells were developed by long term treatment of PEO1 (BRCA2 mutant) and JHOS4 (BRCA1 mutant) ovarian cancer cells with PARPi (AZD2281) or Carboplatin. Cell viability, colony formation, cell cycle and apoptosis were evaluated. Homologous recombination was evaluated by Rad51 foci immuno staining. Replication fork asymmetry was counted by DNA combing assay. PARPi resistant orthotopic PDX models (germline BRCA1/ 2 mutant) were developed by long term treatment with PARPi. PDX developed from a platinum-resistant HGSOC patient with CCNE1 amplification was also tested to evaluate PARPi +/- ATRi. Whole genome sequencing, Reverse-Phase Protein Array Analysis (RPPA) and IHC were performed on cells and xenografts to evaluate for biomarkers of response. Results: ATR/CHK1 pathway was constitutively activated in treatment resistant cell lines. Monotherapy with ATRi alone in vitro modestly induced cell death and DNA damage in PARPi and platinum resistant cell lines. Treatment with ATRi in combination with PARPi is synergistic in reducing survival of these drug resistant cells. Combination treatment was more effective in targeting cell cycle mediators, and promoting apoptosis. HR was restored in PARPi and platinum treatment resistant PEO1 cells. ATRi treatment suppressed restored HR and increased stalled replication fork. PARPi and ATRi combination treatment was synergistic in causing tumor regression in PARPi/Carboplatin resistant PDX models. Conclusions: Our work suggests treatment resistant cells are more dependent on ATR/CHK1 pathway and ATR is a promising target for augmenting PARPi and platinum response in treatment resistant HGSOCs. Citation Format: Hyoung Kim, Erin George, Haineng Xu, Sergey Medvedev, Veena Jagannathan, Mark Morgan, Gordon Mills, Eric Brown, Fiona Simpkins. ATR INHIBITION TARGETS TREATMENT RESISTANT OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr AP31.
PERSISTENCE OF IATROGENIC ATRIAL SEPTAL DEFECT AFTER INTERVENTIONAL MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM: A NOTE OF CAUTION
Authors: Christoph Hammerstingl, Can Öztürk, Robert Schueler, Nikos Werner, Armin Welz, Georg Nickenig
Journal: Journal of the American College of Cardiology (2015)
A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells
Authors: Fumiaki Jinnouchi, Takuji Yamauchi, Ayano Yurino, Takuya Nunomura, Michitaka Nakano, Chika Iwamoto, Teppei Obara, Kohta Miyawaki, Yoshikane Kikushige, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Katsuto Takenaka
Journal: Blood (2020)
Abstract #1355: AXL is strongly activated and a potential target for therapeutic intervention in mesothelioma
Authors: Wen-bin Ou, Raphael Bueno, David Sugarbaker, Jonathan Fletcher
Journal: Cancer Research (2009)

Mesothelioma is a notoriously chemotherapy-resistant neoplasm, which is associated with asbestos exposure. Activation of the receptor tyrosine kinases (TKs) EGFR and MET has been described in subsets of mesothelioma, suggesting that TKs might represent novel therapeutic targets in this lethal disease. We employed the functional proteomic screening approach of phosphotyrosine immunoaffinity purification and tandem mass spectrometry to investigate TK activation in mesothelioma cell lines. The AXL receptor TK protein, which has been shown to have oncogenic properties in non-mesothelial cancer types, was expressed and activated strongly in 9 of 10 mesothelioma cell lines and 6 of 12 mesothelioma biopsies, including 12 of 22 mesotheliomas with spindle-cell histology. Somatic AXL mutations were not found but all cases expressed an alternatively spliced AXL transcript with in-frame deletion of exon 10. AXL silencing by lentivirus-mediated shRNA (short hairpin RNA) in mesotheliomas: 1) inhibited PI3-K/AKT/mTOR and Ras/MAPK signaling pathways; 2) upregulated the cyclin-dependent kinase inhibitors p21 and p27, and tumor suppressor p53; 3) dephosphorylated the cell cycle checkpoint proteins Rb and CDK2; 4) suppressed migration and cellular proliferation due to G1 arrest; and 5) induced apoptosis. These studies implicate AXL as a novel therapeutic target in mesothelioma.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1355.
Letter: Abdominal aortic aneurysms
Authors: G. H. Dixon
Journal: JAMA (1975)

<h3>In Reply—</h3> Angiography, when it can be done with minimal risk, is of value in determining the extent of an aneurysm and the degree of involvement of the aorta and its major branches by occlusive disease. Its use is justified before many, if not all, elective resections of abdominal aortic aneurysms, but it is not usually necessary when the question is one of size alone. When the absence of calcium and other characteristics prevents visualization of aneurysms on plain x-ray films, ultrasonography provides a useful alternative. The importance of the physical examination and plain x-ray films was stressed not because they are the only methods but because they are the most available. Dr Dixon's comments are quite correct.
Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism
Authors: Elisabeth Mahase
Journal: BMJ (2020)

The US Food and Drug Administration (FDA) has withdrawn orphan drug designation from a potential covid-19 treatment, after criticism that treating covid-19 as a rare disease was “disingenuous.”

Pharmaceutical company Gilead requested that the FDA withdraw the designation—which was set to give the company a longer exclusivity period (seven years instead of five) and significant tax incentives—just days after it was given.1

Remdesivir, which works to inhibit viral replication, is a drug currently being investigated as a potential treatment for covid-19 through several clinical trials.

Orphan status is a mechanism designed to promote the development …
TCT-666 Intravascular Ultrasound Derived Minimal Lumen Area Criteria For Functionally Significant Left Main Coronary Artery Stenosis
Authors: Jung-Min Ahn, Young-Rak Cho, Hyo In Choi, Hanul Choi, Soo-Jin Kang, Hyun Kuk Kim, Won-Jang Kim, Young-Hak Kim, Pil Hyung Lee, Jong-Young Lee, Jae Hyung Roh, Duk-Woo Park, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2013)